Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
+Added: Market Information
Our common stock is traded on the Nasdaq Global Select Market under the symbol “AVRO”.
1 unchanged sentence
Prior to that time, there was no established public trading market for our common stock.
−Removed: As of March 6, 2020, the number of holders of record of our common stock was 9.
−Removed: This number does not include beneficial owners whose shares are held in street name.
+Added: Holders of Common Stock
+Added: As of March 5, 2021, the number of holders of record of our common stock was eight.
+Added: The number of holders is based upon the actual number of holders registered in our records at such date and excludes holders in “street name” or persons, partnerships, associations, corporations, or other entities identified in security positions listings maintained by depository trust companies.
We have never declared or paid any cash dividends on our capital stock.
9 unchanged sentences
We did not sell any unregistered equity securities during the period covered by this Annual Report on Form 10-K.
−Removed: Use of Proceeds from Initial Public Offering of Common Stock
−Removed: On June 25, 2018, we completed our initial public offering of 6,035,151 shares of our common stock at a price of $19.00 per share for an aggregate offering price of approximately $114.7 million, including the full exercise of the underwriters’ option to purchase additional shares.
−Removed: Morgan Stanley & Co.
−Removed: LLC, Cowen and Company, LLC, Wells Fargo Securities, LLC and Wedbush Securities Inc.
−Removed: served as the underwriters of the IPO.
−Removed: The offer and sale of all of the shares in the offering were registered under the Securities Act pursuant to a registration statement on Form S-1 (File Nos.
−Removed: 333-225213 and 333-225764), which became effective on June 20, 2018.
−Removed: We received aggregate net proceeds from the offering of approximately $104.0 million, after deducting underwriting discounts and commissions, as well as other offering expenses.
−Removed: No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.
−Removed: As of December 31, 2019, we had used approximately $97.5 million of the net proceeds from the IPO, primarily to fund our current programs in Fabry disease, Gaucher disease, cystinosis, and Pompe disease;
−Removed: our external and internal manufacturing and process development activities related to our programs and to fund research and development activities that relate to all of our clinical and preclinical activities, including the cost of research and development personnel;
−Removed: and general and administrative expenses, working capital and other general corporate purposes.
−Removed: There has been no material change in our planned use of the net proceeds from the offering as described in the final prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act.
−Removed: Selected Financial Data
−Removed: Not Applicable.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.